Efficacy and safety of single‐triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of <i>Helicobacter pylori</i>: an international multicentre study

O’Moráin, Colm; Borody, Thomas J.; Farley, A; Boer, W. A. De; Dallaire, Chrystian; Schuman, Robert W.; Piotrowski, J.; Fallone, Carlo A; Tytgat, G. N. J.; Mégraud, Françis; Spénard, Jean

doi:10.1046/j.1365-2036.2003.01434.x

Cited by 94 publications

(61 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This first-line regimen has a 10% to 23% failure rate. [3][4][5][6][7][8] Evaluation of the effectiveness of the eradication regimen with a reliable tool is important. Except for patients with gastric ulcers at risk of gastric malignancy, the 13 C-urea breath test is confirmed as a reliable noninvasive test to assess the treatment outcome of triple therapy.…”

mentioning

confidence: 99%

Posttreatment 13C-urea breath test is predictive of antimicrobial resistance to H. pylori after failed therapy

et al. 2005

View full text Add to dashboard Cite

OBJECTIVE:We tested whether a 13 C-urea breath test can predict antimicrobial resistance of Helicobacter pylori (H. pylori). METHODS:Seventy patients who had failed triple eradication therapy and 108 untreated H. pylori-infected patients were given a 13 C-urea breath test, endoscopy for culture of H. pylori, and assessment of clarithromycin resistance. The patients who had failed triple therapy then received 1 week of quadruple therapy to eradicate residual H. pylori. RESULTS:The posttreatment value of the 13 C-urea breath test expressed as excessive d 13CO 2 per ml (ECR) was higher in patients with residual H. pylori with clarithromycin resistance than in those without (23.8 vs 10.6; Po.0001). With a cutoff of ECR 4or 15, the 13 C-urea breath test was 88.6% sensitive and 88.9% specific in predicting clarithromycin resistance of residual H. pylori. The H. pylori eradication rate of the rescue regimen was higher for patients with a posttreatment ECR of the 13 C-urea breath test 15 than for those with a value 415 (93.8% vs 73.3%; Po.05). In contrast, in treatment-naive H. pylori-infected patients, the pretreatment value of the 13 C-urea breath test did not differ between patients infected with clarithromycin-resistant or-sensitive isolates (P4.05). CONCLUSION:The posttreatment value of the 13 C-urea breath test is predictive of clarithromycin resistance in residual H. pylori after failed triple therapy and predicts efficacy of the rescue regimen. The value of the noninvasive test is promising for primary care physicians who need to select a rescue regimen without invasive H. pylori culture.

show abstract

mentioning

confidence: 99%

Posttreatment 13C-urea breath test is predictive of antimicrobial resistance to H. pylori after failed therapy

et al. 2005

View full text Add to dashboard Cite

show abstract

“…В некоторых ис-следованиях также использовалось добавление висмута к тройной схеме (ингибитор протонной помпы + амок-сициллин + кларитромицин или левофлоксацин) [33]. При проведении висмутсодержащей квадротерапии от-мечается меньше сложностей, связанных с резистент-ностью: устойчивость к тетрациклину очень низкая и не повышается даже после неудачной терапии, рези-стентность к метронидазолу не уменьшает эффектив-ность висмутсодержащей квадротерапии [34].…”

Section: ключевые слова: H рYlori-инфекция; диагностика; лечение; прunclassified

Маастрихтський Консенсус-5: Аналітичний Огляд Положень

Stepanov¹,

Budzak²

2021

GASTRO

View full text Add to dashboard Cite

show abstract

“…В случае высокой двойной резистентности (к метронидазолу и кларитромицину) рекомендуется квадротерапия с препаратом висмута [36]. При проведе-нии квадротерапии с препаратом висмута возникает меньше проблем, связанных с резистентностью штаммов, т. к. доля устойчивых к тетрациклину штаммов очень небольшая и не возрастает при неэффективной эрадика-ции [53]. Последовательная схема была исключена из перечня схем для эрадикации [36].…”

Section: антихеликобактерная терапияunclassified

Rabeprazole in the treatment of duodenal ulcer desease and functional dyspepsia

Русяев¹,

Шептулин²,

Шульпекова³

et al. 2018

Med. sov.

View full text Add to dashboard Cite

M.Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University) RABEPRAZOLE IN THE TREATMENT OF DUODENAL ULCER DESEASE AND FUNCTIONAL DYSPEPSIA The review aims to provide a contemporary view of the pathogenesis and treatment of the most common duodenum diseasesduodenal ulcer disease (DUD) and functional dyspepsia (FD).Due to its unique structure and functions, the duodenum that anatomically represents the initial section of the small intestine differentiates itself from others. The prevalence of DUD is declining in many Western countries due to the widespread introduction of effective anti-Helicobacter therapy and a significant decrease in the prevalence of H pylori infection. However, the ideas about the poly-biological nature of DUD persists and additional risk factors continue to be studied. DUD is manifested by pain/burning feeling in the epigastric region, as well as by symptoms such as early satiety, epigastric filling after eating in the absence of obvious organic changes in the digestive system. The diagnosis of FD is based on the Rome IV criteria. The duodenum plays an important role in its pathogenesis (disorders of gastric accommodation, motor and visceral hypersensitivity). Most patients with FD have microscopic signs of inflammation of the mucous membrane of the postbulbar part of the duodenum -an increased amount of intraepithelial lymphocytes, eosinophils, and signs of increased permeability of the mucous membrane. In all likelihood, these changes are provoked by infection and / or nutritional factors, as well as by exposure to hydrochloric acid. Proton pump inhibitors (prokinetics in postprandial distress syndrome) form the basis of treatment of peptic ulcer and epigastric pain syndrome; all patients with DUD and dyspepsia syndrome infected with H. pylori receive antihelicobacter therapy. Rabeprazole that is characterized by a long and powerful effect and minimal interaction with the cytochrome 2C19 system stands out from the proton pump inhibitors. Conclusion: acid aggression plays a very important role in the pathogenesis of duodenal ulcers diseases and FD; proton pump inhibitors form the basis for the treatment of such patients both in the form of monotherapy and as part of eradication regimens.

show abstract

Efficacy and safety of single‐triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study

Cited by 94 publications

References 21 publications

Posttreatment 13C-urea breath test is predictive of antimicrobial resistance to H. pylori after failed therapy

Posttreatment 13C-urea breath test is predictive of antimicrobial resistance to H. pylori after failed therapy

Маастрихтський Консенсус-5: Аналітичний Огляд Положень

Rabeprazole in the treatment of duodenal ulcer desease and functional dyspepsia

Contact Info

Product

Resources

About